Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Aligos Therapeutics stock | $15.72

Learn how to easily invest in Aligos Therapeutics stock.

Aligos Therapeutics Inc
- $0.05 ( - 0.32%)

Aligos Therapeutics Inc is a biotechnology business based in the US. Aligos Therapeutics shares (ALGS) are listed on the NASDAQ and all prices are listed in US Dollars. Aligos Therapeutics employs 86 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Aligos Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ALGS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Aligos Therapeutics stock price (NASDAQ: ALGS)

Use our graph to track the performance of ALGS stocks over time.

Aligos Therapeutics shares at a glance

Information last updated 2021-10-23.
Latest market close$15.72
52-week range$13.30 - $37.51
50-day moving average $15.47
200-day moving average $19.97
Wall St. target price$34.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.57

Buy Aligos Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aligos Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aligos Therapeutics price performance over time

Historical closes compared with the close of $15.72 from 2021-10-22

1 week (2021-10-18) -0.13%
1 month (2021-09-24) 15.72
3 months (2021-07-23) -5.02%
6 months (2021-04-23) -35.76%
1 year (2020-10-23) 4.11%
2 years (2019-10-21) N/A
3 years (2018-10-21) N/A
5 years (2016-10-21) N/A

Aligos Therapeutics financials

Revenue TTM $2.5 million
Gross profit TTM $0
Return on assets TTM -44.26%
Return on equity TTM -101.43%
Profit margin 0%
Book value $4.42
Market capitalisation $669.8 million

TTM: trailing 12 months

Shorting Aligos Therapeutics shares

There are currently 1.9 million Aligos Therapeutics shares held short by investors – that's known as Aligos Therapeutics's "short interest". This figure is 9.5% up from 1.7 million last month.

There are a few different ways that this level of interest in shorting Aligos Therapeutics shares can be evaluated.

Aligos Therapeutics's "short interest ratio" (SIR)

Aligos Therapeutics's "short interest ratio" (SIR) is the quantity of Aligos Therapeutics shares currently shorted divided by the average quantity of Aligos Therapeutics shares traded daily (recently around 301243.42313788). Aligos Therapeutics's SIR currently stands at 6.31. In other words for every 100,000 Aligos Therapeutics shares traded daily on the market, roughly 6310 shares are currently held short.

To gain some more context, you can compare Aligos Therapeutics's short interest ratio against those of similar companies.

However Aligos Therapeutics's short interest can also be evaluated against the total number of Aligos Therapeutics shares, or, against the total number of tradable Aligos Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aligos Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Aligos Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0994% of the tradable shares (for every 100,000 tradable Aligos Therapeutics shares, roughly 99 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Aligos Therapeutics.

Find out more about how you can short Aligos Therapeutics stock.

Aligos Therapeutics share dividends

We're not expecting Aligos Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

Aligos Therapeutics overview

Aligos Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company is also developing ALG-020572, an antisense oligonucleotide to decrease HBsAg levels; and ALG-055009, a small molecule THR-ß agonist for the treatment of non-alcoholic steatohepatitis. In addition, it is developing siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. The company has entered into license and collaboration agreements with Luxna Biotech Co. , Ltd.

Frequently asked questions

What percentage of Aligos Therapeutics is owned by insiders or institutions?
Currently 16.779% of Aligos Therapeutics shares are held by insiders and 75.547% by institutions.
How many people work for Aligos Therapeutics?
Latest data suggests 86 work at Aligos Therapeutics.
When does the fiscal year end for Aligos Therapeutics?
Aligos Therapeutics's fiscal year ends in December.
Where is Aligos Therapeutics based?
Aligos Therapeutics's address is: One Corporate Drive, South San Francisco, CA, United States, 94080
What is Aligos Therapeutics's ISIN number?
Aligos Therapeutics's international securities identification number is: US01626L1052

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site